<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetracaine (spinal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetracaine (spinal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tetracaine (spinal): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12316" href="/d/html/12316.html" rel="external">see "Tetracaine (spinal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16054" href="/d/html/16054.html" rel="external">see "Tetracaine (spinal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9591208"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F9565167"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95214460-3eae-4f3d-8c84-52eba66add14">Spinal anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal anesthesia: Injection: Note:</b> Dosage varies with the anesthetic procedure, the degree of anesthesia required, and the individual patient response; it is administered by subarachnoid injection for spinal anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perineal anesthesia:</i> 5 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perineal and lower extremities: </i>10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anesthesia extending up to costal margin:</i> 15 mg; doses up to 20 mg may be given, but are reserved for exceptional cases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low spinal anesthesia (saddle block):</i> 2 to 5 mg.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991832"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989119"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F9565168"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812614"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16054" href="/d/html/16054.html" rel="external">see "Tetracaine (spinal): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95214460-3eae-4f3d-8c84-52eba66add14">Spinal anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal anesthesia:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosage varies with the anesthetic procedure, the degree of anesthesia required, and the individual patient response; doses presented are a reference point (Coté 2019). Doses to be administered by subarachnoid injection for spinal anesthesia. The dose required to produce spinal anesthesia decreases with increasing age; isobaric or hyperbaric 1% solution has been used (Coté 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Age-directed dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;12 weeks: Subarachnoid injection: 0.75 to 1 mg/kg; typically administered as a hyperbaric solution (eg, 1% tetracaine solution mixed in dextrose 10% solution) with or without epinephrine (Coté 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥12 weeks to Children &lt;2 years: Subarachnoid injection: 0.3 to 0.4 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: Subarachnoid injection: 0.2 to 0.3 mg/kg not to exceed the maximum doses shown below.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">5 to 15 kg: Subarachnoid injection: 0.3 to 0.4 mg/kg; should not exceed the maximum doses shown below (Coté 2013; Miller 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 kg: Subarachnoid injection: 0.2 to 0.3 mg/kg; should not exceed the maximum doses shown below (Coté 2013; Miller 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maximum</i>
<i> doses</i>: Subarachnoid injection: Should not exceed usual procedure-specific adult doses:</p>
<p style="text-indent:-2em;margin-left:6em;">Perineal anesthesia: 5 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Perineal and lower extremities: 10 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia extending up to the costal margin: 15 mg; doses up to 20 mg may be given but are reserved for exceptional cases.</p>
<p style="text-indent:-2em;margin-left:6em;">Low spinal anesthesia (saddle block): 2 to 5 mg.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729849"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729850"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9565125"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Adverse effects listed are those characteristics of local anesthetics. Systemic adverse effects are generally associated with excessive doses or rapid absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills, dizziness, drowsiness, loss of consciousness, nervousness, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision, miosis</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Tinnitus</p></div>
<div class="block coi drugH1Div" id="F9564887"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tetracaine, ester-type anesthetics, aminobenzoic acid, or any component of the formulation; injection should not be used when spinal anesthesia is contraindicated</p></div>
<div class="block war drugH1Div" id="F9564888"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including rhythm disturbances, shock, or heart block.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased plasma esterase levels: Use with caution in patients with abnormal or decreased levels of plasma esterases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obstetric patients: Use with caution in obstetric patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with increased intra-abdominal pressure: Use with caution in patients with increased intra-abdominal pressure; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well-trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F9565208"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (2 mL)</p></div>
<div class="block geq drugH1Div" id="F9564879"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322498"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tetracaine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $45.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F9565170"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Before injection, withdraw syringe plunger to make sure injection is not into vein or artery.</p></div>
<div class="block admp drugH1Div" id="F52614412"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Subarachnoid injection: May administer as an isobaric or hyperbaric solution by experienced individuals only. Before injection, withdraw syringe plunger to make sure injection is not into vein or artery (Coté 2019).</p></div>
<div class="block use drugH1Div" id="F9564882"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Spinal anesthesia:</b> For the production of spinal anesthesia for procedures requiring 2 to 3 hours</p></div>
<div class="block cyt drugH1Div" id="F13300123"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9565129"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F9564885"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F17917023"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if tetracaine (systemic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetracaine (systemic) to nursing women. </p></div>
<div class="block pha drugH1Div" id="F9565158"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
<div class="block phk drugH1Div" id="F9565160"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of action: 1.5 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; detoxified by plasma esterases to aminobenzoic acid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58207190"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dicaine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tetracaine pch</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tetocaine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pantocain | Pantocain steril | Tetracaine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amethocaine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Pontocaine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pontocaine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tetocaine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dicain</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17056977">
<a name="17056977"></a>Corcoran W, Butterworth J, Weller RS, et al, “Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,” <i>Anesth Analg</i>, 2006, 103(5):1322-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/17056977/pubmed" id="17056977" target="_blank">17056977</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia Children</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier Saunders; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al, “Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,” <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17448066">
<a name="17448066"></a>Foxall G, McCahon R, Lamb J, et al, “Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,” <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/17448066/pubmed" id="17448066" target="_blank">17448066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10981258">
<a name="10981258"></a>Gregory PJ and Matsuda K, “Cetacaine Spray-Induced Methemoglobinemia After Transesophageal Echocardiography,” <i>Ann Pharmacother</i>, 2000, 34(9):1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/10981258/pubmed" id="10981258" target="_blank">10981258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16616636">
<a name="16616636"></a>Lavergne S, Darmon M, Levy V, et al, “Methemoglobinemia and Acute Hemolysis After Tetracaine Lozenge Use," <i>J Crit Care</i>, 2006, 21(1):112-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/16616636/pubmed" id="16616636" target="_blank">16616636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16867094">
<a name="16867094"></a>Litz RJ, Popp M, Stehr SN, et al, “Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion," <i>Anaesthesia</i>, 2006, 61(8):800-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/16867094/pubmed" id="16867094" target="_blank">16867094</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, eds. <i>Miller's Anesthesia</i>. 7th ed. Churchill, Livingstone, Elsevier; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20332339">
<a name="20332339"></a>Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, “State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,” <i>Ann Pharmacother</i>, 2010, 44(4):688-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/20332339/pubmed" id="20332339" target="_blank">20332339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16810015">
<a name="16810015"></a>Rosenblatt MA, Abel M, Fischer GW, et al, “Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,” <i>Anesthesiology</i>, 2006, 105(1):217-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/16810015/pubmed" id="16810015" target="_blank">16810015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6968187">
<a name="6968187"></a>Sandza JG Jr, Roberts RW, Shaw RC, et al, “Symptomatic Methemoglobinemia With a Commonly Used Topical Anesthetic, Cetacaine,” <i>Ann Thorac Surg</i>, 1980, 30(2):187-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/6968187/pubmed" id="6968187" target="_blank">6968187</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tetracaine 1% [prescribing information]. Louisville, KY: Cameron Pharmaceuticals LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9043560">
<a name="9043560"></a>van Kan JH, Egberts AC, Rijnvos WP, et al, “Tetracaine Versus Lidocaine-Prilocaine for Preventing Venipuncture-Induced Pain in Children,” <i>Am J Health Syst Pharm</i>, 1997, 54(4):388-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracaine-spinal-drug-information/abstract-text/9043560/pubmed" id="9043560" target="_blank">9043560</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9931 Version 155.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
